Neurocrine Biosciences (NBIX) Total Non-Current Liabilities (2010 - 2026)

Neurocrine Biosciences' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 27.57% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 27.57% YoY) and the FY2025 annual result came in at $1.2 billion, up 20.35% from the prior year.
• Total Non-Current Liabilities was $1.2 billion for Q1 2026 at Neurocrine Biosciences, up from $1.2 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.2 billion in Q1 2026 and bottomed at $554.3 million in Q2 2022.
• A 5-year average of $834.1 million and a median of $777.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities dropped 14.49% — and 2025, when it soared 56.57%.
• Neurocrine Biosciences' Total Non-Current Liabilities stood at $631.2 million in 2022, then jumped by 44.66% to $913.1 million in 2023, then increased by 5.44% to $962.8 million in 2024, then grew by 20.35% to $1.2 billion in 2025, then advanced by 6.84% to $1.2 billion in 2026.
• Business Quant data shows NBIX's Total Non-Current Liabilities at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.